Linda Duska, MD
Gynecologic Oncology · Charlottesville, VANPI 1447241807
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Merck at 55.2% of the total. 2025 is the largest year on record at $31,515, 2.8 times the $11,169 reported in 2019. Among gynecologic oncology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 58 payments — averaging $1235.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$40K
- Corcept Therapeutics$6K
- Tesaro, Inc.$6K
- Aadi Bioscience, Inc.$5K
- Eisai Inc.$4K
- Karyopharm Therapeutics Inc.$3K
- plus $8K from 6 others
Across 319 payments — averaging $23,024 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3.4M
- GSK$1.2M
- AstraZeneca$670K
- Blueprint Medicines Corporation$421K
- Novartis$390K
- Eisai Inc.$262K
- plus $1M from 11 others
What the payments were for
- Consulting fees$38,03253%
- Speaking & faculty fees$30,59043%
- Travel & lodging$1,7602%
- Food & beverage$1,1702%
- Education$1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 23 | $39,586 |
| Corcept Therapeutics | 7 | $6,239 |
| Tesaro, Inc. | 9 | $5,712 |
| Aadi Bioscience, Inc. | 5 | $5,232 |
| Eisai Inc. | 2 | $3,825 |
| Karyopharm Therapeutics Inc. | 2 | $3,301 |
| GSK | 2 | $2,915 |
| AbbVie | 1 | $2,494 |
| Regeneron | 1 | $2,085 |
| AstraZeneca | 3 | $160 |
| Genentech USA, Inc. | 1 | $105 |
| Intuitive Surgical | 2 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$71,677 in reported general payments places this provider in the 90th percentile of 47 gynecologic oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Megestrol Acetate | 23 | $452 |
| Dexamethasone | 22 | $342 |
| Ondansetron Hcl | 26 | $228 |
| Prochlorperazine Maleate | 32 | $209 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Charlottesville
- Samantha BatmanCharlottesville$76K
- Marilyn HuangCharlottesville$39K
- Kari RingCharlottesville$14K
- Susan ModesittCharlottesville$4K
- Charles LandenCharlottesville$3K
- Leigh CantrellCharlottesville$460
- Jaime KiffCharlottesville$82
- Cecelia BoardmanRichmond$577K
- Leslie RandallFairfax$342K
- Chad HamiltonAnnandale$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.